CR20160192A - Formulación de farmaco de liberación retardada - Google Patents

Formulación de farmaco de liberación retardada

Info

Publication number
CR20160192A
CR20160192A CR20160192A CR20160192A CR20160192A CR 20160192 A CR20160192 A CR 20160192A CR 20160192 A CR20160192 A CR 20160192A CR 20160192 A CR20160192 A CR 20160192A CR 20160192 A CR20160192 A CR 20160192A
Authority
CR
Costa Rica
Prior art keywords
formulation
pharmaco
delayed release
release
delayed
Prior art date
Application number
CR20160192A
Other languages
English (en)
Inventor
Felipe José Oliviera Varum
Gonzalez Roberto Carlos Bravo
Thomas Buser
Adbul Wase Basit
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CR20160192A publication Critical patent/CR20160192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En una formulación de liberación retardada que comprende un núcleo que contiene unfármacoyun recubrimiento de liberación retardada para proporciona la liberación intestinal, la liberación del fármacoen el colon se acelera mediante la inclusión de una capa aislante entre el núcleo y el recubrimiento de liberación retardada.
CR20160192A 2013-10-29 2016-04-25 Formulación de farmaco de liberación retardada CR20160192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
CR20160192A true CR20160192A (es) 2016-07-13

Family

ID=49515360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160192A CR20160192A (es) 2013-10-29 2016-04-25 Formulación de farmaco de liberación retardada

Country Status (25)

Country Link
US (1) US10799515B2 (es)
EP (2) EP3542791A1 (es)
JP (1) JP6273356B2 (es)
KR (2) KR102174942B1 (es)
CN (2) CN105555260B (es)
AU (2) AU2013404367B2 (es)
BR (2) BR122020013726B1 (es)
CA (1) CA2923063C (es)
CR (1) CR20160192A (es)
CU (1) CU20160055A7 (es)
EA (1) EA032504B1 (es)
HK (1) HK1222547A1 (es)
IL (2) IL244260B (es)
MA (1) MA38847B2 (es)
MX (2) MX382146B (es)
MY (1) MY189394A (es)
NZ (2) NZ717159A (es)
PH (2) PH12020551522A1 (es)
SA (2) SA116370660B1 (es)
SG (1) SG11201600501UA (es)
TN (1) TN2016000119A1 (es)
TW (3) TWI680774B (es)
UA (1) UA117260C2 (es)
WO (1) WO2015062640A1 (es)
ZA (1) ZA201600630B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187171B1 (en) 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
EP3728061A4 (en) * 2017-12-21 2021-09-08 Pepsico Inc MULTI-INGREDIENT POP-UP DRINK CAPSULE FOR PREPARING A DRINK
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CA3160869C (en) * 2019-12-11 2024-06-25 Priyanka HAKSAR Dosage form for use in treating or preventing of a disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DE69907479T2 (de) 1999-12-16 2004-04-08 Laboratorio Medinfar-Produtos Farmacéuticos, S. A. Piroxicam enthaltende gastrointestinale Zubereitung aus merheren Einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2002096405A1 (en) * 2001-05-25 2002-12-05 Ssp Co., Ltd. Drug preparations
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20100285123A1 (en) 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US20090175935A1 (en) * 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) * 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
DK2152250T3 (da) 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
KR101573889B1 (ko) 2009-10-09 2015-12-04 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
EP3187171B1 (en) 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Also Published As

Publication number Publication date
BR112016004863A8 (pt) 2020-02-11
EP3542791A1 (en) 2019-09-25
CN105555260B (zh) 2021-04-23
IL244260B (en) 2021-08-31
KR102174942B1 (ko) 2020-11-06
CA2923063A1 (en) 2015-05-07
US20160250232A1 (en) 2016-09-01
WO2015062640A1 (en) 2015-05-07
ZA201600630B (en) 2017-05-31
KR20160077040A (ko) 2016-07-01
BR112016004863B1 (pt) 2022-09-20
EA032504B1 (ru) 2019-06-28
MA38847A1 (fr) 2017-08-31
PH12016500307A1 (en) 2016-05-16
BR122020013726B1 (pt) 2022-11-01
NZ747731A (en) 2020-02-28
TW202011945A (zh) 2020-04-01
EP3062776A1 (en) 2016-09-07
MX382146B (es) 2025-03-13
US10799515B2 (en) 2020-10-13
IL265381A (en) 2019-05-30
TWI725458B (zh) 2021-04-21
PH12020551522A1 (en) 2022-11-14
CN110279669A (zh) 2019-09-27
AU2013404367B2 (en) 2020-02-27
CA2923063C (en) 2021-09-07
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
CN110279669B (zh) 2022-02-15
AU2020201365B2 (en) 2021-09-16
MX2019002162A (es) 2019-06-17
TW201944984A (zh) 2019-12-01
UA117260C2 (uk) 2018-07-10
HK1222547A1 (zh) 2017-07-07
JP2016535030A (ja) 2016-11-10
MX388063B (es) 2025-03-19
MX2016001840A (es) 2016-08-11
TN2016000119A1 (en) 2017-10-06
MY189394A (en) 2022-02-09
AU2013404367A1 (en) 2016-02-18
IL265381B (en) 2022-05-01
JP6273356B2 (ja) 2018-01-31
SA114360006B1 (ar) 2016-11-09
TWI680774B (zh) 2020-01-01
AU2020201365A1 (en) 2020-03-12
EA201690596A1 (ru) 2016-08-31
MA38847B2 (fr) 2021-02-26
SA116370660B1 (ar) 2019-02-24
TW201542243A (zh) 2015-11-16
KR102237356B1 (ko) 2021-04-08
PH12016500307B1 (en) 2022-02-11
CU20160055A7 (es) 2016-10-28
CN105555260A (zh) 2016-05-04
KR20200075041A (ko) 2020-06-25
IL244260A0 (en) 2016-04-21
NZ717159A (en) 2019-06-28

Similar Documents

Publication Publication Date Title
CR20160192A (es) Formulación de farmaco de liberación retardada
CR20140486A (es) Formulacion de farmaco de liberacion retardada
DOP2016000024A (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
UA117008C2 (uk) IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
ECSP18015616A (es) Tableta
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
UY35731A (es) Éteres de arilo y sus usos
AR091465A1 (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influenciar positivamente la microbiota intestinal
MX2018012800A (es) Administracion de metabolitos de berberina.
DK3020407T3 (da) Traditionel kinesisk medicinsk sammensætning, samt fremstilling og anvendelse heraf
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
CL2016001431A1 (es) Producto de confitería congelado con un recubrimiento de gel que se desprende fácilmente y un método para elaborarlo
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
UA117833C2 (uk) Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування
BR112016015190A2 (pt) Composição farmacêutica não contendo antioxidante e método de preparação da mesma
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
MX2019001225A (es) Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo.
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
AR102408A1 (es) Laminados de sustratos de cerámica
AR101143A1 (es) Envase
UY36140A (es) Formulación de ceritinib
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona